Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alkem LaboratoriesNSE:ALKEM -0.56%97 EV-to-EBIT is 21.00 as of Aug. 14, 2026, which is 8% below its 10-year median of 22.85. GuruFocus rates NSE:ALKEM with a GF Score™ of 97/100 and a GF Value™ of ₹6,117.42 (Modestly Undervalued). Among 682 Drug Manufacturers companies, Alkem Laboratories ranks worse than 59.09% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Alkem Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was ₹618,683 Mil.
Alkem Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹30,317 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkem Laboratories EV-to-EBIT Related Terms
Alkem Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Alkem Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkem Laboratories EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Alkem Laboratories's EV-to-EBIT falls into.
Alkem Laboratories's current Enterprise Value is ₹636,677 Mil.
Alkem Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹30,317 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkem Laboratories (NSE:ALKEM) has a EV-to-EBIT of 21.00 as of Aug. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alkem Laboratories and its competitors. This is near median its historical median of 22.85. Over the past decade, Alkem Laboratories' EV-to-EBIT has ranged from 16.77 to 33.07. According to the industry distribution chart, Alkem Laboratories ranks #403 out of 682 companies in the Drug Manufacturers industry, placing it in the top 59.1%.
Is Alkem Laboratories' EV-to-EBIT too high?
Alkem Laboratories' current EV-to-EBIT of 21.00 is near median its 10-year median of 22.85. Over the past 10 years, this metric has ranged from a low of 16.77 to a high of 33.07. The Drug Manufacturers industry median EV-to-EBIT is 15.86. Alkem Laboratories' value of 21.00 is 32.5% above this industry median. Based on the distribution chart, Alkem Laboratories ranks #403 out of 682 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alkem Laboratories has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkem Laboratories' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alkem Laboratories ranks #403 out of 682 companies for EV-to-EBIT. This places Alkem Laboratories in the lower half of its industry. The industry median EV-to-EBIT is 15.86. Alkem Laboratories' value of 21.00 is 32.5% above this benchmark. Historically, Alkem Laboratories' own EV-to-EBIT has ranged from 16.77 to 33.07 over the past decade. While the company's 10-year median is 22.85 vs. the industry median of 15.86, Alkem Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkem Laboratories's current EV-to-EBIT of 21.00 is 32.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alkem Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkem Laboratories's current EV-to-EBIT is 21.00, which is near median its own 10-year median of 22.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkem Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alkem Laboratories (NSE:ALKEM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹6,117.42, compared to a current price of ₹5,449.50 — trading 10.9% below its estimated fair value. The current EV-to-EBIT is 21.00, which is near median its 10-year median of 22.85 and 32.5% above the Drug Manufacturers industry median of 15.86. Alkem Laboratories' overall GF Score™ is 97/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Alkem Laboratories (NSE:ALKEM), the current EV-to-EBIT is 21.00 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkem Laboratories (NSE:ALKEM) Overvalued in 2026?
Based on GuruFocus' analysis, Alkem Laboratories stock appears to be undervalued.
The current stock price of ₹5,449.50 is trading 10.9% below its estimated GF Value™ of ₹6,117.42.
GuruFocus considers Alkem Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:ALKEM:
EV-to-EBIT: 21.00 (near median its 10-year median of 22.85)
GF Value™: ₹6,117.42 vs. price of ₹5,449.50 (10.9% below fair value)
Industry Position: 32.5% above the Drug Manufacturers median (#403 of 682)
No single metric tells the full story. See the NSE:ALKEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
97GF Score
Get the complete analysis for NSE:ALKEM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALKEM has been successfully added to your 
